Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 4 years ago

Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

@xconomy.com 5 years ago

Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges

@xconomy.com 5 years ago

To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango

@xconomy.com 5 years ago

Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections

@xconomy.com 5 years ago

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

@xconomy.com 6 years ago

United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed